Catalent is Investing $230M to Expand its Gene Therapy Manufacturing Campus Near BWI
Life sciences company Catalent Pharma Solutions LLC is planning to invest $230M to expand its Catalent Cell and Gene Therapy campus for manufacturing gene therapy treatments near BWI Airport. The company plans to add three additional viral-vector manufacturing suites to its existing Anne Arundel County facility, maximizing capacity to produce treatments that transfer genetic material into cells to fight rare diseases. Catalent’s presence in Greater Baltimore dates to 2018, when it acquired Baltimore-founded Paragon Bioservices in a deal worth $1.2B. The company continues to have a facility at the University of Maryland BioPark in Baltimore City where it works on manufacturing for developmental phases. The company plans to add 700 new employees at the Anne Arundel site in scientific, technical and operational roles over the next six years. Via Technical.ly.